Glivara Clinical | Obesity Medication Management + Clinic Workflows

One question for obesity-medicine clinicians

Which parts of obesity medication management create the most friction or take the most time in your practice?

Choose up to four. Add Other if something's missing.

Medication access, coverage, or prior authorization Patient education and expectation setting Medication initiation, titration, or follow-up Side-effect, adherence, or persistence support Staff handoffs and escalation Documentation and care coordination Other

Full name required

Role or credentials required

Practice or organization optional

Professional email required

I'm also open to a conversation about a founding-clinic collaboration.

Please don't include patient information. This form is for practice-level input only and is not for protected health information. Your answers help shape future topics for The AOM Practice Brief. Glivara Clinical will not publicly identify you or your practice. See the Privacy Notice.

Next, you'll be invited to subscribe to The AOM Practice Brief.

Skip the question and go straight to the Brief

What Glivara is exploring

The medication work that surrounds obesity care

Anti-obesity medications bring a steady stream of work that sits between the prescription and the patient: coverage steps, starts and dose changes, follow-up, side-effect questions, and handoffs. Glivara Clinical is a clinical consulting company being built around that work, starting by listening to the practices that carry it.

Medication-management systems

How practices move through access and coverage, initiation and titration, follow-up, and tolerability support, and where those steps keep returning to the clinician.

Clinic workflows

Handoffs, escalation, documentation, and coordination: who owns the next step, and how consistently it happens across the team.

A pharmacist's perspective

Protocol-driven, collaborative medication management, applied to the operational side of an obesity-medicine practice.

Learning with founding practices

Early conversations with practice owners in Maryland and Washington, DC will shape what Glivara builds, and what it doesn't.

Founder

C. Gina Anglin, PharmD

Founder & Clinical Pharmacist

Fourteen years of clinical pharmacy experience
Ambulatory care, hospital and health-system, and government and public-health practice
Collaborative-practice and protocol-driven medication management

Glivara Clinical brings that experience to the systems obesity-medicine practices rely on every day: the education, follow-up, handoffs, and escalation that make medication management work.

Newsletter

The AOM Practice Brief by Glivara Clinical

A pharmacist-led briefing for owners and leaders of obesity-medicine practices: the obesity-medication developments that matter, and what they may mean for clinical care, medication access, and clinic workflow.

New drugs, indications, formulations, and meaningful safety developments
Coverage, cash pricing, manufacturer programs, shortages, and access
Important trials, guidelines, and regulatory changes
Implications for initiation, titration, switching, monitoring, and follow-up
What practice owners should watch, verify, or prepare for

Monthly, plus occasional urgent updates when something major changes. First issue coming soon. Subscribing takes one click after you answer the question above.

Answer the question to get the Brief

Curious about shaping this from the start?

Glivara is looking to learn alongside a small number of owner-led obesity-medicine practices in Maryland and Washington, DC. If that sounds interesting, tick the founding-clinic box when you answer the question above. It's simply an invitation to talk, with no commitment.